Investor FAQ

This resource provides in-depth information to address frequently asked inquiries, offering clarity and support for anyone looking for more information.

MEGA was listed on 19th November 2013 on Stock exchange of Thailand.

MEGA is a leading participant in the health and wellness industry in developing countries. Our business may be categorized into three segments:

  • Mega We CareTM branded products business: We develop, manufacture, market and sell our own brand of market leading nutraceutical products, prescription pharmaceutical products and OTC products which are sold in 36 developing countries
  • MaxxcareTM distribution business: We market, sell and distribute various branded prescription pharmaceutical products, OTC and FMCG products. We operate our MaxxcareTM distribution business in three countries, namely, Myanmar, Vietnam and Cambodia. Our clients for this business segment include leading domestic and international pharmaceutical and FMCG companies, and
  • OEM business: In addition to manufacturing our own branded products, our manufacturing facilities in Thailand and Australia accept various production orders from third-party customers.

We have 3 types of products under Mega We CareTM branded products business:

  • Nutraceutical: Products which provide health benefits in addition to the basic nutritional value found in normal diet. Skin health, general health/Immunity, Liver health, men’s/women health and bones health are the key categories.
  • Prescription: Medicines only available for purchase by consumers with a medical prescription. Diabetology, dermatology, gastroenterology and orthopedics are the key therapeutic categories.
  • OTC: Medicines sold directly to consumer without a prescription from a healthcare professional. Analgesics, gastroenterology and cough and cold are the key therapeutic categories.

Yes, MEGA has 2 manufacturing facilities in Thailand (approved by German health authorities, Thai FDA and TGA Australia), 1 in Australia (approved by TGA Australia) and 1 in Indonesia (approved by Indonesian FDA). A significant portion of total products sold under Mega We CareTM segment are manufactured in-house

Southeast Asia is the largest market contributing 77% of Mega We CareTM revenue in FY 2021

MEGA is a leading international distributor of pharmaceutical and OTC products in the Myanmar, Vietnam and Cambodia. MEGA also enjoys a leading position in the distribution of consumer products in Myanmar and Cambodia.

As at 31 December 2021, MEGA had 16 warehouses and offices across Myanmar, Vietnam and Cambodia, robust information systems and more than 2,400 skilled employees which allows MEGA to be at the forefront in providing world class service.

Myanmar is the largest market contributing more than 77% of MaxxcareTM distribution business in FY2021.